Premium
POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL
Author(s) -
Diefenbach C,
Abrisqueta P,
Gonzalez-Barca E,
Panizo C,
Arguinano Perez J. Maria,
Miall F,
Bastos-Oreiro M,
Lopez-Guillermo A,
Banerjee L,
McMillan A,
Hirata J,
Musick L,
Saha S,
Croft B,
Seymour E
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.155_2880
Subject(s) - medicine , neutropenia , tolerability , lenalidomide , rituximab , febrile neutropenia , diffuse large b cell lymphoma , gastroenterology , refractory (planetary science) , adverse effect , surgery , lymphoma , oncology , chemotherapy , multiple myeloma , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom